NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
Gynecol Oncol, 188, 103-110 (in press)
DOI 10.1016/j.ygyno.2024.06.017, PubMed 38943691
Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
Cancers (Basel), 16 (11)
DOI 10.3390/cancers16112084, PubMed 38893205
Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
Int J Gynecol Pathol (in press)
DOI 10.1097/PGP.0000000000001030, PubMed 38847524